Eli Lilly and Co (LLY) Forecasted to Earn FY2019 Earnings of $4.74 Per Share

Eli Lilly and Co (NYSE:LLY) – Equities researchers at Leerink Swann issued their FY2019 EPS estimates for Eli Lilly and in a report issued on Monday. Leerink Swann analyst S. Fernandez expects that the company will post earnings of $4.74 per share for the year. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Eli Lilly and’s FY2020 earnings at $4.98 EPS and FY2021 earnings at $5.41 EPS.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, January 31st. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $0.98 by $0.03. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. The business had revenue of $5.76 billion for the quarter, compared to the consensus estimate of $5.54 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/2485836/eli-lilly-and-co-lly-forecasted-to-earn-fy2019-earnings-of-4-74-per-share.html.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Several other research analysts also recently commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $97.00 price objective (up from $95.00) on shares of Eli Lilly and in a report on Saturday, March 11th. Vetr downgraded shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $74.30 price target for the company. in a report on Tuesday, January 31st. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Tuesday, January 24th. Credit Suisse Group AG reissued a “buy” rating on shares of Eli Lilly and in a report on Tuesday, March 21st. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $73.00 price target (up from $70.00) on shares of Eli Lilly and in a report on Wednesday, February 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Eli Lilly and presently has a consensus rating of “Buy” and a consensus target price of $88.70.

Eli Lilly and (NYSE:LLY) traded down 0.06% during trading on Wednesday, reaching $81.89. The company had a trading volume of 3,499,417 shares. The company has a market capitalization of $86.06 billion, a price-to-earnings ratio of 31.74 and a beta of 0.30. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72. The company has a 50-day moving average price of $84.25 and a 200 day moving average price of $77.93.

In related news, major shareholder Lilly Endowment Inc sold 230,000 shares of Eli Lilly and stock in a transaction on Friday, February 17th. The shares were sold at an average price of $80.27, for a total value of $18,462,100.00. Following the transaction, the insider now owns 125,125,804 shares in the company, valued at approximately $10,043,848,287.08. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Donald A. Zakrowski sold 2,000 shares of Eli Lilly and stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $77.52, for a total transaction of $155,040.00. Following the completion of the transaction, the insider now owns 886 shares in the company, valued at approximately $68,682.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 688,162 shares of company stock worth $55,440,777. Corporate insiders own 0.20% of the company’s stock.

A number of institutional investors have recently modified their holdings of the company. First Command Financial Services Inc. boosted its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the last quarter. Integrated Wealth Management boosted its position in shares of Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock worth $112,000 after buying an additional 50 shares during the last quarter. Financial Architects Inc boosted its position in shares of Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock worth $114,000 after buying an additional 61 shares during the last quarter. Tarbox Group Inc. boosted its position in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares during the last quarter. Finally, LeJeune Puetz Investment Counsel LLC acquired a new position in shares of Eli Lilly and during the fourth quarter worth approximately $136,000. Institutional investors own 75.15% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barclays Comes Up Short, Shares Fall
Barclays Comes Up Short, Shares Fall
Revenue at Twitter Beats the Street, Monthly Users Increase
Revenue at Twitter Beats the Street, Monthly Users Increase
McDonald’s Ordering Via Mobile Could Give Handsome Return
McDonald’s Ordering Via Mobile Could Give Handsome Return
Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor


Leave a Reply

© 2006-2017 Ticker Report. Google+.